glp-1 for ckd Design and discovery of a highly potent ultralong-acting and glucagon co-agonist attenuating renal fibrosis image1.png

Egrifta SV launched commercially in 2020 March 25, 2025 Egrifta WR (tesamorelin F8) Approval Ready-to-use formulation approved no reconstitution required, improved patient convenience Approved Indication Tesamorelin (Egrifta) is specifically FDA-approved for: Indication: Reduction of excess abdominal fat in HIV-infected patients with lipodystrophy HIV-associated lipodystrophy is a metabolic condition causing abnormal fat distribution, particularly visceral adipose tissue (VAT) accumulation around abdominal organs

The active molecule semaglutide is identical to the ingredient in brand-name Wegovy and Ozempic

Make everyday life noticeably easier Since I started the capsules, I stick to meals more easily, crave sweets less and feel satisfied sooner

Weight loss, achieved through a balanced diet and regular exercise, can reduce uric acid levels and lessen the frequency of gout attacks